 | Up a level |
Roth, A. D.; Maibach, R.; Fazio, N.; Sessa, C.; Stupp, R.; Morant, R.; Herrmann, R.; Borner, M. M.; Goldhirsch, A.; De Braud, F. (2004). 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere®)–cisplatin in advanced gastric carcinoma: a phase I–II trial. Annals of oncology, 15(5), pp. 759-764. Oxford University Press 10.1093/annonc/mdh187
Crivellari, D.; Pagani, O.; Veronesi, A.; Lombardi, D.; Nolè, F.; Thürlimann, B.; Hess, D.; Borner, M.; Bauer, J.; Martinelli, G.; Graffeo, R.; Sessa, C.; Goldhirsch, A. (2001). High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Annals of oncology, 12(3), pp. 353-356. Oxford University Press 10.1023/A:1011132609055
Pagani, O.; Sessa, C.; Nolè, F.; Crivellari, D.; Lombardi, D.; Thürlimann, B.; Hess, D.; Borner, M.; Bauer, J.; Martinelli, G.; Graffeo, R.; Zucchetti, M.; D'Incalci, M.; Goldhirsch, A. (2000). Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: A multicentric phase I–II study. Annals of oncology, 11(8), pp. 985-991. Oxford University Press 10.1023/A:1008392927656
Pagani, O.; Sessa, C.; Martinelli, G.; Crivellari, D.; Buonadonna, A.; Thürlimann, B.; Hess, D.; Borner, M.; Bauer, J.; Zampino, G.; Zimatore, M.; Graffeo, R.; Riva, A.; Goldhirsch, A. (1999). Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Annals of oncology, 10(5), pp. 539-545. Oxford University Press 10.1023/A:1026437731354
Cerny, T.; Leyvraz, S.; Von Briel, T.; Küpfer, A.; Schaad, R.; Hsu Schmitz, S.-F.; Honegger, P.; Sessa, C.; Brunner, J.; Boddy, A. V. (1999). Saturable metabolism of continuous high-dose ifosfamide with Mesna and GM-CSF: A pharmacokinetic study in advanced sarcoma patients. Annals of oncology, 10(9), pp. 1087-1094. Oxford University Press 10.1023/A:1008386000547
Sessa, C.; Minoia, C.; Ronchi, A.; Zucchetti, M.; Bauer, J.; Borner, M.; De Jong, J.; Pagani, O.; Renard, J.; Weil, C.; D'Lncalci, M. (1998). Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. Annals of oncology, 9(12), pp. 1315-1322. Oxford University Press 10.1023/A:1008441416790
Stupp, R.; Bauer, J.; Pagani, O.; Gerard, B.; Cerny, T.; Sessa, C.; Bastian, G.; Sarkany, M.; Schläpfer, J.; Giroux, B.; Leyvraz, S. (1998). Ventricular arrhythmia and torsade de pointe: Dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. Annals of oncology, 9(11), pp. 1233-1242. Oxford University Press 10.1023/A:1008495919071
Pagani, O.; Sessa, C.; Martinelli, G.; Cerny, Thomas; De Jong, J.; Goldhirsch, A.; Zimatore, M.; Cavalli, F. (1997). Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer. Annals of oncology, 8(7), pp. 655-661. Oxford University Press 10.1023/A:1008211629858
Buser, K.; Bacchi, M.; Goldhirsch, A.; Greiner, R.; Diener, P.; Sessa, C.; Jungi, W. F.; Forni, M.; Leyvraz, S.; Engeler, V. (1996). Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiation. Annals of oncology, 7(1), pp. 65-70. Oxford University Press 10.1093/oxfordjournals.annonc.a010481
